KMLE
»çÀÌÆ® ¼Ò°³
°Ë»ö
°Ë»ö¾î Áö¿ì±â
´Ý±â
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
°í±Þ °Ë»ö ¼³Á¤
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
14
ÆäÀÌÁö:
4
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¼¼Å©·Î½Åĸ½¶
Cefaclor 250 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
621¿ø/1 °³
ÇǸ¤»êĸ½¶
Buflomedil Pyridoxal Phosphate 200 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
278¿ø/1 °³
À̼ҵð¿£ÁÖ
Diluted Isosorbide Dinitrate 10 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/10 °³
ºñ½º¸¶¾×
Tripotassium Bismuth Dicitrate 20 mg
ȯÀÎÁ¦¾à
ÀϹÝ|»èÁ¦
0¿ø/1 °³
·Ï½º·Î½ÅÁ¤
Roxithromycin 150 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
À¯¹Ù½Ç¸°ÁÖ750mg
Sulbactam Sodium 250 mg, Ampicillin Sodium 500 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
2256¿ø/1 °³
¸ÞÇÁÁ¹Ä¸½¶
Omeprazole Enteric Coated Granule 230 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
903¿ø/1 °³
Æø¼¼Æ¾Ä¸½¶
Fluoxetine HCl 22.4 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
396¿ø/1 °³
À¯¹ÙÆäÁ¸ÁÖ1g
Sulbactam Sodium 500 mg, Cefoperazone Sodium 500 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Ä«µð¾ÆÁª¼¹æÄ¸½¶180mg
Diltiazem HCl S.R. Pellet 259.06 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦(ºñ±Þ¿©Àüȯ)
0¿ø/1 °³
Å©·»Å¹ÁÖ
Diclofenac Beta-Dimethyl Aminoethanol 90
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/3 °³
¹ÝÄÚ½ºÅ¸½ÅÁÖ1g
Vancomycin HCl 1 g
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
ȯÀÎÅ©·ÎÇȼÖÁ¤10mg
Zuclopenthixol Hydrochloride 11.82 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
ÆÄ½ºÅ׳îÁ¤50mg
Atenolol 50 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
visual hallucination
ȯ½Ã
reducing sugar
ȯ¿ø´ç
reducing substance
ȯ¿ø¹°Áú
reducing factor
ȯ¿øÀÎÀÚ
reductimetry
ȯ¿øÀûÁ¤
reduction potential
ȯ¿øÀüÀ§
reductant
ȯ¿øÁ¦
reducing agent
ȯ¿øÁ¦, ȯ¿ø½Ã¾à
reducible hernia
ȯ¿øÅ»Àå
reduced hemoglobin
ȯ¿øÇ÷»ö¼Ò, ȯ¿øÇì¸ð±Û·Îºó
reduced flavoprotein
ȯ¿øÇüÇöóºó´Ü¹éÁú
reducing enzyme
ȯ¿øÈ¿¼Ò
reductase
ȯ¿øÈ¿¼Ò
patient
ȯÀÚ
case comparison study
ȯÀÚ´ëÁ¶±º¿¬±¸
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
base pair substitution
¿°±â½Öġȯ
biotransformation
»ýü³»º¯È¯
blastic transformation
¸ð¼¼Æ÷Àüȯ
bleeder¡¯s disease
Ç÷¿ìº´, ÃâÇ÷¼ºÈ¯ÀÚº´
blood-testis barrier
Ç÷¾×°íȯÀ庮
breathing reserve
1. È£Èí¿¹ºñ 2. ȯ±â¿¹ºñ·® 3. È£Èí¿¹ºñ·Â
bullet
ÃѾË, źȯ
Cabot ring
Ä«º¸Æ®È¯
circuit system
¼øÈ¯½Äȸ·Î
circular insanity
¼øÈ¯Á¤½ÅÀÌ»ó
circular reaction
¼øÈ¯¹ÝÀÀ
circulating blood volume
¼øÈ¯Ç÷¾×·®
circulating immune complex
¼øÈ¯¸é¿ªº¹ÇÕü
circulation
¼øÈ¯
circulation time
¼øÈ¯½Ã°£
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
nyctalope
¹ã¼Ò°æ, ¾ß¸ÍȯÀÚ
nosepiece
Àüȯ±â
oxidation-reduction
»êÈȯ¿ø
outpatient
¿Ü·¡È¯ÀÚ
oligopnea
(¢¡ hypoventilation) È£ÈíÀúÇÏ, ȯ±âÀúÇÏ
orchiopexy
°íȯ°íÁ¤¼ú
orchiorrhaphy
(¢¡orchiopexy) °íȯ°íÁ¤¼ú
orchitis
°íȯ¿°
orchiectomy
°íȯÀýÁ¦¼ú
orchiditis
(¢¡orchitis) °íȯ¿°
plasmapheresis
Ç÷ÀåºÐ¸®±³È¯¼ú
polyorchism
´Ù°íȯÁõ, ¿©·¯°íȯÁõ
periorchitis
°íȯÁÖÀ§¿°
pellet
ħÀü¹°, ħ»ç, ȯ¾à
psychedelic
1.ȯ°¢Á¦, 2.ȯ°¢-
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
reflux condenser
ȯ·ù³Ã°¢±â
gustatory hallucination
ȯ¹Ì, ¹Ì°¢È¯°¢
reduced heat
ȯ»ê¿·®
calibration scale
ȯ»êÇ¥
fantasy
ȯ»ó
phantasm
ȯ»ó
phantom
ȯ»ó, ¸ðÇü
annular psoriasis
ȯ»ó°Ç¼±
circinate balanitis
ȯ»ó±ÍµÎ¿°
tinea circinata
ȯ»ó¹é¼±Áõ
phantom limb
ȯ»ó»çÁö, ȯ»óÆÈ´Ù¸®
phantom limb phenomenon
ȯ»ó»çÁöÇö»ó
phantom lover syndrome
ȯ»ó¿¬ÀÎÁõÈıº
phantom pregnancy
ȯ»óÀÓ½Å
pseudologia fantastica
ȯ»óÀû°ÅÁþ¸»
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
capillaropathy
¸ð¼¼°üº´Áõ, ¸ð¼¼Ç÷°üÁúȯ
carbocyclic
ź¼Òȯ-
cardiac
½ÉÀå-, µé¹®-, ½ÉÀ庴ȯÀÚ
cardiacos negros
Èæ»ö½ÉÀ庴ȯÀÚ
cardioversion
½ÉÀåÀ²µ¿Àüȯ
cardioverter
½ÉÀåÀ²µ¿Àüȯ±â
chemodynesis
ÈÇÐÀ¯±â, ÈÇÐÀû¼¼Æ÷Áúȯ·ùÁÖµµ
circulation
¼øÈ¯
circulator
¼øÈ¯±â
circulatory
¼øÈ¯-
commutation
±³È¯
comorbidity
Áߺ¹ÀÌȯ, µ¿¹ÝÀÌȯ
compatible
ȣȯ-, ÇÕ´ç-
convalescent
ȸº¹±â-, ȸº¹±âȯÀÚ
conversion
Àüȯ
ÀÌÀü
´ÙÀ½
Sponsored Links
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
annulus migrans
ȯ»óÀ̵¿
annular placenta
ȯ»óŹÝ(ü»ßÒ÷ÃÚï), À±»óŹÝ.
hallucination, visual
ȯ½Ã(ü³ãÊ)
globule
ȯ¾à, (¼Ò)±¸.
pill rolling tremor
ȯ¾àÁ¶Á¦¾çÁøÀü(ü¯å·ðàð¥ åÆòèïµ)
pill rolling tremor
ȯ¾àÁ¶Á¦¾çÁøÀü(ü¯å·ðàð¥ åÆòèïµ).
pill rolling tremor
ȯ¾àÁ¶Á¦¾çÁøÀü(ü¯å·ðàð¥åÆòèïµ)
apparition
ȯ¿µ(ü³ç±)
reducing atmosphere
ȯ¿ø(¼º) ´ë±â.
reduction
ȯ¿ø(ü½êª), °¨¼Ò.
reducing sugar
ȯ¿ø´ç(ü½êªÓØ).
reducing substances
ȯ¿ø¹°Áú
reducible hernia =repondible h.
ȯ¿ø¼º Ç츣´Ï¾Æ(ü½êªàõ¡)
reducible hernia =reponible h.
ȯ¿ø¼º(ȯ¿ø¼º) Ç츣´Ï¾Æ.
reduction discharge
ȯ¿ø¼º¹æ.
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
Waldeyers (tonsillar) ring
¿Ðµ¥ÀÌ¾î ÆíµµÈ¯, ±¸°³ÀÎµÎÆíµµ
Willis circle
Àª¸®½º ȯ(ü»)
aberrant cycle
ÀÌ»ó¼øÈ¯(ì¶ßÈâàü»)
abortive transformation
ºÒ¹ßÇüÁúÀüȯ, ºÎÀüÇüÁúÀüȯ
absent testes syndrome
°íȯ°á¿©ÁõÈıº
absorbed dose conversion factor
Èí¼ö¼±·®º¯È¯°è¼ö
acid perfusion
»ê°ü·ù(߫δêü), »êȯ·ù.
acoustic transducer
À½Ç⺯ȯ±â
acquired cystic disease of the kidney
ÈÄõ¼º ½Å³¶Æ÷Áúȯ
acquired heart disease =AHD
ÈÄõ¼º ½ÉÁúȯ(¡ãýòðü´).
acute auditory hallucinosis
±Þ¼º ȯûÁõ
acute demyelinating disease
±Þ¼º Å»¼öÃʼº Áúȯ(¡÷âÐõ¦àõòðü´).
acute epididymitis
±Þ¼º ºÎ°íȯ¿°
acute epididymoorchitis
±Þ¼º °íȯºÎ°íȯ¿°
acute hallucinatory paranoia
±Þ¼º ȯ»ó¼º ÆíÁýº´(Ðáàõü³ßÌàõø¶òûÜ»).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
environmental temperature
ȯ°æ¿Âµµ.
milieu therapy
ȯ°æ¿ä¹ý(ü»ÌÑèþÛö).
environmental cause
ȯ°æ¿øÀÎ
environmental sanitation
ȯ°æÀ§»ý, ȯ°æÀ§»ýÇÐ.
environmental health
ȯ°æÀ§»ý.
environmental hygiene
ȯ°æÀ§»ý.
environmental threat
ȯ°æÀ§Çù.
environmental medicine
ȯ°æÀÇÇÐ.
habitat factor
ȯ°æÀÎÀÚ(Ì·ËËöËö), ÁÖ°Å ÀÎÀÚ.
environmental factor
ȯ°æÀÎÀÚ.
environmental hazard
ȯ°æÀçÇØ, ȯ°æÀåÇØ.
environmental condition
ȯ°æÁ¶°Ç(ÊÙ̡˧).
environmental disruption
ȯ°æÆÄ±«.
environmental damage
ȯ°æÇÇÇØ.
hexiology
ȯ°æÇÐ(Ì·Ḛ̈).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
alpha chain disease
¾ËÆÄ¼âÁúȯ
alpha-chain disease
¾ËÆÄ¼â Áúȯ(¡áð òðü´)
alternate case method
±³´ëȯÀÚ¿ä¹ý.
alternate paired case method
±³´ë´ë¸³È¯ÀÚ¿ä¹ý(ÎßÓÛÓßí¡ü´íºèþÛö).
aluminothermics
¾Ë·ç¹Ì´½È¯¿ø¾ß±Ý¹ý(¡ü½êªå§ÐÝÛö).
alusia
ȯ°¢(ü³ÊÆ).
alveolar gas exchange
ÆóÆ÷±âü±³È¯(¡Îß üµ)
alveolar gas exchange
ÆóÆ÷°¡½º±³È¯(¡Îß üµ).
alveolar hypoventilation
ÆóÆ÷Àúȯ±â(¡î¸üµÑ¨).
alveolar hypoventilation syndrome
ÆóÆ÷Àúȯ±âÁõÈıº.
alveolar ventilation
ÆóÆ÷ȯ±â(·®)
alveolar ventilation rate
ÆóÆ÷ȯ±âºñ(¡üµÑ¨Ýï)
alveolar ventilation volume
ÆóÆ÷ȯ±â¿ëÀû
ambient
ȯ°æ(Ì·Ë)ÀÇ, ÁÖÀ§ÀÇ.
amblyope
¾à½Ã(ȯ)ÀÚ(å°ãÊü´íº).
ÀÌÀü
´ÙÀ½
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
Inferior ligament of epididymis
¾Æ·¡ºÎ°íȯÀδë
[¿¾ ¿ë¾î] ÇϺΰíȯ°£¸·
Anterior atlanto-occipital membrane
¾Õ°í¸®µÚÅë¼ö¸·
[¿¾ ¿ë¾î] ÀüȯÃßÈĵθ·
Perichondrial bony ring
¿¬°ñ¸·»À°í¸®
[¿¾ ¿ë¾î] ¿¬°ñ¸·¼º°ñȯ
Right testicular vein
¿À¸¥°íȯÁ¤¸Æ
[¿¾ ¿ë¾î] ¿ì°íȯÁ¤¸Æ
Left testicular vein
¿Þ°íȯÁ¤¸Æ
[¿¾ ¿ë¾î] Á°íȯÁ¤¸Æ
Superior ligament of epididymis
À§ºÎ°íȯÀδë
[¿¾ ¿ë¾î] »óºÎ°íȯ°£¸·
Median atlanto-axial joint
Á¤Áß°í¸®Áß¼è°üÀý
[¿¾ ¿ë¾î] Á¤ÁßȯÃà°üÀý
Embryonic circulation
žƼøÈ¯
[¿¾ ¿ë¾î] žƼøÈ¯
Annulus of flagellum
Æí¸ð°í¸®
[¿¾ ¿ë¾î] Æí¸ðȯ
Anulus of flagellum
Æí¸ð°í¸®
[¿¾ ¿ë¾î] Æí¸ðȯ
Chemical environment
ÈÇÐȯ°æ
[¿¾ ¿ë¾î] ÈÇÐÀû¿øÀÎ
Environmental cause
ȯ°æ¿øÀÎ
[¿¾ ¿ë¾î] ȯ°æÀû¿øÀÎ
Testis
°íȯ
[¿¾ ¿ë¾î] °íȯ(Á¤¼Ò)
Testis
°íȯ
[¿¾ ¿ë¾î] °íȯ[Á¤¼Ò]
Septum testis
°íȯ°¡·Î¸·
[¿¾ ¿ë¾î] °íȯ[Á¤¼Ò]Áß°Ý
ÀÌÀü
´ÙÀ½
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÇÑÀÚ
polycystic kidney d.
´Ù³¶½ÅÁúȯ
ÒýÒ¥àõ ãìòðü´
rheumatoid d.
·ù¸¶Æ¼½º¾çÁúȯ
·ù¸¶Æ¼½ºåÆòðü´
self-limited d.
ÀÚ°¡Ä¡À¯Áúȯ
í»Ê«ùÚïÒàõòðü´
systemic d.
Àü½ÅÁúȯ
îïãóòðü´
conversion d.
ÀüȯÀå¾Ö
ï®üµî¡äô
demyelinating d.
¸»ÀÌÁýÅ»¶ôÁúȯ
¸»ÀÌÁý ÷Õª òðü´
seizure d.
¹ßÀÛÁúȯ
Û¡íÂòðü´
vascular d.
Ç÷°üÁúȯ
úìηî¡äô
dyscrasia
Áúȯ, º´
òðü´,Ü»
feedback
µÇ¸ÔÀÓ, ±Íȯ
Ïýü½
auditory h.
µè±âȯ°¢, ȯû
ü³ôé
formed h
Á¤Çüȯ°¢
ïÚû¡ü³ÊÆ
gustatory h.
¹Ì°¢È¯°¢, ȯ¹Ì
ü³Ú«
ictal h.
¹ßÀÛȯ°¢
Û¡íÂü³ÊÆ
olfactory h.
³¿»õȯ°¢, ȯÃë
ü³ö«
ÀÌÀü
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
dissimilatory reduction
ÀÌÈ È¯¿ø(ì¶ûùü½êª)
disulfide interchange
ÀÌȲȹ°±³È¯(ì£üÜü§ÚªÎßüµ)
electron-exchange resin
ÀüÀÚ±³È¯ ¼öÁö(ï³íÎßüµâ§ò·)
energy transduction
¿¡³ÊÁö Àüȯ(ï®üµ)
enzyme interconversion
È¿¼Ò »óÈ£Àüȯ (ý£áÈßÓû»ï®üµ)
equatorial substituent
¼öÆò¹æÇâ ġȯ±â (â©øÁÛ°ú¾öÇüµÐñ)
equatorial substitution
¼öÆò¹æÇâ ġȯ (â©øÁÛ°ú¾öÇüµ)
ester interchange
¿¡½ºÅÍ »óÈ£±³È¯ (ßÓû»Îßüµ)
exchange diffusion
±³È¯ È®»ê (Îßüµüªß¤)
Fabry's disease
ÆÄºê¸® Áúȯ (òðü´)
Farber's disease
ÆÄ¾Æ¹ö Áúȯ(òðü´)
ferredoxin reducing substance
Æä¸®µ¶½Å ȯ¿ø ¹°Áú(ü½êªÚªòõ)
Forbe`s disease
Æ÷ºê Áúȯ(òðü´)
Fourier transform infrared spectroscopy
Ǫ¸®¿¡ º¯È¯(ܨüµ) Àû¿Ü¼±ºÐ±¤±¤µµ¹ý(îåèâàÊÝÂÎÃÎÃÓøÛö)
Fourier transform nuclear magnetic resonance
Ǫ¸®¿¡ º¯È¯(ܨüµ) ÇÙÀÚ±â°ø¸í(ú·í¸Ñ¨ÍìÙ°)
ÀÌÀü
´ÙÀ½
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
disease
º´, Áúº´, Áúȯ
diversion
±âºÐÀüȯ, ¿À¶ô
driven equilibrium Fourier transform sequence
ÃßÁøÆòÇüFourierº¯È¯¿¬¼â
ductus epididymis
ºÎ°íȯ°ü, ºÎ°íȯü°ü
dyscrasia
Áúȯ, ¾Ç¾×Áú
ectopic testicle
À̼Ұíȯ
endocrine disease
³»ºÐºñÁúȯ
epididymal duct
ºÎ°íȯ°ü
epididymis
ºÎ°íȯ
epididymitis
ºÎ°íȯ¿°
eunuch
³»½Ã, ȯ°ü, °Å¼¼µÈ »ç¶÷
eunuchoid
À¯È¯°ü
exchange coupling
±³È¯°áÇÕ
exchange diffusion
±³È¯È®»ê
exchange guide wire
±³È¯¿ëÀ¯µµÃ¶»ç
ÀÌÀü
´ÙÀ½
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
4
ÄÚµå
¿µ¹®
ÇѱÛ
B20.2
HIV disease resulting in cytomegaloviral disease
°Å´ë¼¼Æ÷¹ÙÀÌ·¯½º ÁúȯÀ» À¯¹ßÇÑ HIVº´
B20.8
HIV disease resulting in other infectious and parasitic diseases
±âŸ °¨¿°¼º ¹× ±â»ýÃæ¼º ÁúȯÀ» À¯¹ßÇÑ HIVº´
B20.9
HIV disease resulting in unspecified infectious or parasitic disease
»ó¼¼ºÒ¸íÀÇ °¨¿°¼º ¶Ç´Â ±â»ýÃæ¼º ÁúȯÀ» À¯¹ßÇÑ HIVº´
B22
Human immunodeficiency virus [HIV] disease resulting in other specified diseases
±âŸ ¸í½ÃµÈ ÁúȯÀ» À¯¹ßÇÑ ÀÎü¸é¿ª°áÇ̹ÙÀÌ·¯½ºº´
B22.7
HIV disease resulting in multiple diseases classified elsewhere
´Þ¸® ºÐ·ùµÈ ´Ù¹ß¼º ÁúȯÀ» À¯¹ßÇÑ HIVº´
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
¼³¸í
phantom limb pain
ȯ»óÁöÅë, ȯ°¢ÁöÅë, ȯÁöÅë
1. Àý´ÜÇÏ¿© ¾ø¾îÁø »çÁö¿¡ ÀÏ¾î³´Ù°í »ý°¢ÇÏ´Â µ¿Åë. 2. ÀÌ¹Ì Àý´ÜÇØ¼ »ó½ÇÇÑ ÆÈ´Ù¸®°¡ ¾ÆÁ÷ ÀÖ´Â °Íó·³ ´À³¢°í ±×°÷¿¡ ÅëÁõÀ» ´À³¢´Â °ÍÀ» ¸»ÇÑ´Ù. Àý´ÜÁöÀÇ ½Å°æ ¸»´ÜºÎ¿¡ ¼øÈ¯ Àå¾Ö³ª À¯Âø ¹ÝÈçÀÌ ÀÖÀ¸¸é »ý±â±â ½±´Ù. °ßµð±â ¾î·Á¿î ÀÛ¿ÅëÀÌ ÀÖ°í Á¤½ÅÀûÀ¸·Î Æò¿ÂÇÑ »óÅ¿¡¼´Â ÅëÁõµµ Àû´Ù.
anulus migrans
ȯ¼º ÆíµÎÅë
c-AMP level
ȯ½Ä AMP ·¹º§
deoxidizing
ȯ¿ø
ÈÇÐÀûÀ¸·Î °áÇÕµÈ »ê¼Ò¸¦ Á¦°ÅÇÏ´Â °Í.
reverse mutation
ȯ¿ø µ¹¿¬ º¯ÀÌ
reducing flux
ȯ¿ø À¶Á¦
reducase
ȯ¿ø È¿¼Ò
»ý¸®ÇÐÀûÀ¸·Î ´Ù¸¸ ´ë»ç¹°ÀÇ È¯¿ø¿¡¸¸ ÀÌ¿ëµÇ´Â ¹ÝÀÀÀ» Ã˸ÅÇÏ´Â »êÈ È¯¿ø È¿¼Ò Á¾·ùÀÇ ÇÑ È¿¼Ò.
desoxydation
ȯ¿ø, Å»»ê¼Ò
reducing agent
ȯ¿øÁ¦, ȯ¿ø ¹°Áú
reducible
ȯ¿øÇÒ ¼ö ÀÖ´Â
ringing artifact
ȯÀΰø¹°
parhelion
ȯÀÏ
žçÀÇ ¾çÂÊ¿¡ ³ªÅ¸³ª´Â ÀÏÁ¾ÀÇ ±¤»óÀ¸·Î, ¹é»ö ¶Ç´Â ¿¯Àº »ö並 ¶í´Ù.
patient
ȯÀÚ
1. ÀÇÇÐÀû Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷, ƯÈ÷ º´¿ø¿¡¼. 2. ÀÇ»ç, Ä¡°ú ÀÇ»ç µî¿¡ µî·ÏµÇ¾î Çʿ信 µû¶ó ±×¿¡°Ô Ä¡·á¸¦ ¹Þ´Â »ç¶÷.
rights of patients
ȯÀÚ ±Ç¸®, ȯÀÚÀÇ ±Ç¸®
chart
ȯÀÚ ±â·ÏÁö, µµÇ¥, ÇØµµ, º´·ÂÁö
¾î¶² º¯¼ö, ¿¹ÄÁ´ë ¸Æ¹Ú, ü¿Â, È£Èí¼ö º¯µ¿ µîÀÇ ´Ü¼øÈµÈ ±×¸² Ç¥½Ã, ¶Ç´Â ƯÁ¤ÇÑ Áõ·Ê ÀüüÀÇ ÀÓ»ó ¼Ò°ßÀÇ ±â·Ï.
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
¼³¸í
attack rate
¹ßº´·ü, ÀÌȯÀ²
auxotherapy
ġȯ¿ä¹ý
È£¸£¸ó ¿ä¹ýÀ̳ª Àå±â¿ä¹ý°ú °°Àº ´ë»ó¿ä¹ý.
band contouring plier
´ëȯºÎÇü °âÀÚ
band pusher
´ëȯ ÃßÁø±â
band splint
´ëȯ ºÎ¸ñ
between-patient variability
ȯÀÚ°£ º¯È
bioreductive drug
»ýü ȯ¿ø¼º ¾àÁ¦
biosphere
´ë»ýȰ±Ç, »ý¹° ȯ°æ ¹ÝÀÀ±Ç, »ý¹°±Ç
´ë±â±Ç, ¼ö±Ç ¹× ¾Ï¼®±Ç µî »ý¹°ÀÌ Á¸ÀçÇÏ´Â Àü¼¼°èÀÇ ÀϺÎ. »ý¹°°ú ȯ°æ°£ÀÇ È°µ¿ ¿µ¿ª.
blood volume
Ç÷¾×·®, Ç÷¾× ¼øÈ¯·®
c-AMP level
ȯ½Ä AMP ·¹º§
Cabot's ring bodies
Ä«º¸Æ® ȯ»óü
ÁßÁõ ºóÇ÷ ȯÀÚÀÇ ÀûÇ÷±¸¿¡¼ º¼ ¼ö Àִ ȯ»ó ¶Ç´Â 8ÀÚÇüÀÇ ¼±À̸ç, Wright-Leishman ¿°»öü¿¡¼ Àû»öÀ¸·Î, ¿°È ¸ÞƿŸÀÌ¿À´ÑÀÇ ¿¡¿À»êȹ° ¿°»ö¿¡¼ û»öÀ¸·Î ¿°»öµÈ´Ù.
calcicosis cutis circumscripta
ȯ±¹¼º ÇǺΠ¼®È¸Áõ
ÇÇºÎ¿Í ÇÇÇÏÃþ¿¡¼ÀÇ Ä®½·¿°ÀÇ ºÎºÐÀûÀÎ Ä§Âø Çö»ó. ÁÖÀ§ Á¶Á÷¿¡¼´Â ÈçÈ÷ À°¾ÆÁ¶Á÷ÀÌ ¹ß°ßµÈ´Ù.
capsular articularis atlantooccipitalis
ȯÃß ÈĵΠ°üÀý³¶
½ÖÀ¸·Î µÇ¾î ÀÖ´Â º°°³ Àδ뼺 ´ëÀÇ Çϳª. °¢°¢Àº ±× ÇÑÂÊ ´ÜÀÌ È¯Ãß ¿ÜÃø±«¿¡, ´Ù¸¥ ´ÜÀº Èĵΰñ°úÀÇ °¡ÀåÀÚ¸®¿¡ ºÎÂøÇϰí ÀÖ´Ù.
carbonaceous exchanger
ź¼º ġȯü
cardiovascular collapse
½É Ç÷°ü ÇãÅ», ¼øÈ¯ ÇãÅ»
ÀÌÀü
´ÙÀ½
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
10
ÆäÀÌÁö:
4
³×¿À¸¶ÂðÁ¤100mg
A09700281
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Chlorpromazine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
ȯÀÎÅ©·ÎÇȼÖÁ¤10mg
A09701841
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Zuclopenthixol
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
ȯÀÎÅ©·ÎÇȼÖÁ¤25mg
A09701851
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Zuclopenthixol
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
ȯÀο°»êŬ·Î¹ÌÇÁ¶ó¹Îݼ¿10mg
A09702221
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Clomipramine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ¹Ì»ý»ê
ȯÀο°»êŬ·Î¹ÌÇÁ¶ó¹Îĸ½¶25mg
A09702231
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Clomipramine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
µ¦»ç´ýÅ©¸²
A09703401
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Dexamethasone propionate
±¸ºÐ/º¸Çè±Þ¿©: ÀϹÝÀǾàǰ | ±Þ¿©
¹Ù·ùÁ¦ÆÊÁ¤2mg
G01000171
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Diazepam
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
¹Ù·ùÁ¦ÆÊÁ¤5mg
G01000181
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Diazepam
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ¹Ì»ý»ê
¹Ù·»Å¹Á¤25mg
A09702391
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Diclofenac sodium
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ¹Ì»ý»ê
Å©·»Å¹ÁÖ
A09750771
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Diclofenac-beta-dimethyl-aminoethanol
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
entourage
ȯ°æ;ÁÖÀÇ;Ãø±Ù
acclimate
ȯ°æ¿¡ ¼øÀÀ½ÃŰ´Ù
euthenics
ȯ°æ¿ì»ýÇÐ;»ýȰ°³¼±ÇÐ
ecoactivist
ȯ°æ¿îµ¿°¡
environmental
ȯ°æÀÇ;ÁÖÀ§ÀÇ;ȯ°æ¿¹¼úÀÇ(environmental pollution ȯ°æ ¿À¿°)
environmental warfart
ȯ°æÀü(ȯ°æÀ» ¹Ù²Ù°Å³ª ÆÄ±«ÇÏ´Â Àü·«)
ecocide
ȯ°æÆÄ±«
environmentology
ȯ°æÇÐ
exchange control
ȯ°ü¸®
cambist
ȯ°ü¸®¾÷¹«¿¡ ¹àÀº »ç¶÷;ȯ ¸Å¸ÅÀÎ;ȯÀü»ó;°¢±¹ ÅëÈ.µµ·®Çü ºñ±³Ç¥
money crop
ȯ±Ý ÀÛ¹°
cash crop
ȯ±Ý ÀÛ¹°;½ÃÀå¿ë ÀÛ¹°
ventilation
ȯ±â
ventilator
ȯ±â ¼³ºñ;ÅëdzÀåÄ¡;Åëdz±â;¼Ûdz±â;Åëdz°ø;Åëdz°ü;ȯ±ââ;(¸ðÀÚÀÇ)¹Ù¶÷ ±¸¸Û;ȯ±â ´ã´çÀÚ;¿©·Ð¿¡ È£¼ÒÇϱâ À§ÇÏ¿© ¹®Á¦¸¦ Á¦±âÇÏ´Â »ç¶÷
hyperventilation
ȯ±â(È£Èí) Ç×Áø;°úȯ±â
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
inpatient
ÀÔ¿øÈ¯ÀÚ
insinuate
³ÍÁö½Ã ¸»ÇÏ´Ù; ȯ½ÉÀ» »ç´Ù
jubilant
ȯ¼ºÀ» ¿Ã¸®´Â
jubilation
ȯÈñ; ȯȣ
make restitution
»óȯ(¹è»ó)ÇÏ´Ù
make up to
ȯ½ÉÀ» »ç·Á°íÇÏ´Ù; Á¢±ÙÇÏ´Ù
malady
Áúȯ
metonymic
ȯÀ¯ÀûÀÎ
metonymical
ȯÀ¯ÀûÀÎ
milieu
ȯ°æ; Ç¥Çö¼ö´Ü
mirth
ȯÈñ; ¼Òµ¿; ¿ôÀ½
operator
Á¶ÀÛÀÚ,Àüȱ³È¯¿ø
paranoiac
ÆíÁýº´ ȯÀÚ
parheliacal
ȯÀÏÀÇ
parhelic
ȯÀÏÀÇ
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
4
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½